Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)
6,930.00
-40.00 (-0.57%)
At close: Sep 11, 2025
Daehan Nupharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 201,517 | 202,187 | 204,223 | 197,957 | 166,586 | 149,293 | Upgrade |
Other Revenue | -0 | -0 | - | -0 | -0 | -0 | Upgrade |
201,517 | 202,187 | 204,223 | 197,957 | 166,586 | 149,293 | Upgrade | |
Revenue Growth (YoY) | -0.35% | -1.00% | 3.16% | 18.83% | 11.58% | 11.33% | Upgrade |
Cost of Revenue | 106,658 | 106,710 | 111,986 | 109,403 | 84,994 | 75,100 | Upgrade |
Gross Profit | 94,859 | 95,477 | 92,236 | 88,554 | 81,593 | 74,193 | Upgrade |
Selling, General & Admin | 70,499 | 70,585 | 63,237 | 56,799 | 50,779 | 43,640 | Upgrade |
Research & Development | 4,857 | 1,329 | 4,106 | 2,284 | 2,156 | 1,812 | Upgrade |
Other Operating Expenses | 982.3 | 1,027 | 4,394 | 744.91 | 680.51 | 658.82 | Upgrade |
Operating Expenses | 79,699 | 76,812 | 73,377 | 60,605 | 55,210 | 50,949 | Upgrade |
Operating Income | 15,159 | 18,665 | 18,859 | 27,949 | 26,383 | 23,244 | Upgrade |
Interest Expense | -1,778 | -1,760 | -1,762 | -1,254 | -907.33 | -1,013 | Upgrade |
Interest & Investment Income | 293.84 | 397.17 | 1,084 | 405.63 | 233.54 | 126.53 | Upgrade |
Earnings From Equity Investments | -357.13 | -466.76 | -142.53 | -26.5 | - | -26,074 | Upgrade |
Currency Exchange Gain (Loss) | 70.4 | -113.09 | -193.13 | -230.6 | -216.93 | -66.97 | Upgrade |
Other Non Operating Income (Expenses) | 268.41 | 372.02 | 289.66 | 9,275 | -1,347 | -7,732 | Upgrade |
EBT Excluding Unusual Items | 13,657 | 17,094 | 18,136 | 36,119 | 24,145 | -11,515 | Upgrade |
Gain (Loss) on Sale of Investments | -893.07 | 1,281 | 2,547 | -1,608 | -564.19 | -1,156 | Upgrade |
Gain (Loss) on Sale of Assets | -0.53 | -0.53 | -0.53 | 9.51 | -0.36 | - | Upgrade |
Pretax Income | 12,763 | 18,375 | 20,683 | 34,520 | 23,580 | -12,671 | Upgrade |
Income Tax Expense | 2,526 | 2,907 | 8,141 | 10,203 | 7,886 | -2,551 | Upgrade |
Net Income | 10,237 | 15,468 | 12,542 | 24,317 | 15,694 | -10,120 | Upgrade |
Net Income to Common | 10,237 | 15,468 | 12,542 | 24,317 | 15,694 | -10,120 | Upgrade |
Net Income Growth | -18.15% | 23.33% | -48.42% | 54.95% | - | - | Upgrade |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 14 | 14 | Upgrade |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 14 | Upgrade |
EPS (Basic) | 729.37 | 1102.08 | 893.60 | 1732.58 | 1118.17 | -721.04 | Upgrade |
EPS (Diluted) | 729.37 | 1102.08 | 893.60 | 1732.58 | 1118.17 | -721.04 | Upgrade |
EPS Growth | -18.15% | 23.33% | -48.42% | 54.95% | - | - | Upgrade |
Free Cash Flow | -40,577 | -14,083 | 2,830 | 10,822 | 5,958 | 4,082 | Upgrade |
Free Cash Flow Per Share | -2891.09 | -1003.40 | 201.62 | 771.04 | 424.51 | 290.83 | Upgrade |
Gross Margin | 47.07% | 47.22% | 45.16% | 44.73% | 48.98% | 49.70% | Upgrade |
Operating Margin | 7.52% | 9.23% | 9.23% | 14.12% | 15.84% | 15.57% | Upgrade |
Profit Margin | 5.08% | 7.65% | 6.14% | 12.28% | 9.42% | -6.78% | Upgrade |
Free Cash Flow Margin | -20.14% | -6.97% | 1.39% | 5.47% | 3.58% | 2.73% | Upgrade |
EBITDA | 19,328 | 22,763 | 22,340 | 31,177 | 29,712 | 26,271 | Upgrade |
EBITDA Margin | 9.59% | 11.26% | 10.94% | 15.75% | 17.84% | 17.60% | Upgrade |
D&A For EBITDA | 4,168 | 4,098 | 3,481 | 3,228 | 3,330 | 3,027 | Upgrade |
EBIT | 15,159 | 18,665 | 18,859 | 27,949 | 26,383 | 23,244 | Upgrade |
EBIT Margin | 7.52% | 9.23% | 9.23% | 14.12% | 15.84% | 15.57% | Upgrade |
Effective Tax Rate | 19.79% | 15.82% | 39.36% | 29.56% | 33.45% | - | Upgrade |
Advertising Expenses | - | 3,069 | 3,654 | 3,456 | 4,184 | 6,309 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.